Novo Nordisk's Lotte Bjerre Knudsen says her determination is a key part of the success, but she also stays humble.

The German Diabetes Society (DDG) issued a warning concerning a rise in pregnancies among women using injectable medications ...

Tirzepatide, a new injectable weight-loss drug with the trade name Zepbound, reduced the risk of diabetes in patients with obesity and prediabetes by more than 90% over a three-year period ...

J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...

Including the acquisition and expansion of the manufacturing facility, Eli Lilly will be investing $4bn in the site. After ...

The Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) trial was a randomized, placebo-controlled trial that enrolled 17,604 patients over 45 with pre-existing ...

This article reviews the published evidence over two decades of use of the NovoPen ® family of injection devices in diabetes management. A search for NovoPen ® publications from 1985 onwards was ...

It would have been impossible to predict then that she'd become instrumental in the development of the popular class of injectable diabetes and weight loss drugs like Ozempic and Wegovy that have ...

It was her research and development of Novo Nordisk's first daily GLP-1 shot for diabetes (liraglutide, approved in the US in 2010) that would spur the development of those more powerful ...

Specifically, she focused her research on injectable peptides ... her teams at Novo Nordisk invented an entirely new class of diabetes and weight loss drugs, she's still level-headed about ...